Richard L. ZuWallack, MD a,b, James P

Slides:

Advertisements

Similar presentations

Efficacy and safety overview of a new inhaled corticosteroid, QVAR (hydrofluoroalkane- beclomethasone extrafine inhalation aerosol), in asthma Jennifer.

Advertisements

W.Travis Cain, MDa, Greg Cable, PhDb, John J. Oppenheimer, MDc

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Ulrich Wahn, MDa. ‡, Eli O. Meltzer, MDb. ‡, Albert F. Finn, MDc

Zafirlukast improves asthma symptoms and quality of life in patients with moderate reversible airflow obstruction Robert A. Nathan, MDa, Jonathan A.

Comparative efficacy and anti-inflammatory profile of once-daily therapy with leukotriene antagonist or low-dose inhaled corticosteroid in patients with.

A randomized, vehicle-controlled trial of tacrolimus ointment for treatment of atopic dermatitis in children Mark Boguniewicz, MDa, Virginia C. Fiedler,

Efficacy of combination treatment with anti-IgE plus specific immunotherapy in polysensitized children and adolescents with seasonal allergic rhinitis

Rosa Codina, PhD, Richard F. Lockey, MD

Comparison of once-daily ebastine 20 mg, ebastine 10 mg, loratadine 10 mg, and placebo in the treatment of seasonal allergic rhinitis Paul H. Ratner,

Roflumilast combined with montelukast versus montelukast alone as add-on treatment in patients with moderate-to-severe asthma Eric D. Bateman, MD, Udo-Michael.

Badrul A. Chowdhury, MD, PhD

Hydroxychloroquine improves airflow and lowers circulating IgE levels in subjects with moderate symptomatic asthma B.Lauren Charous, MD, Elkan F. Halpern,

Multicenter, double-blind, placebo-controlled, multiple-challenge evaluation of reported reactions to monosodium glutamate Raif S. Geha, MDa, Alexa Beiser,

Effect of inhaled fluticasone with and without salmeterol on airway inflammation in asthma Annika Wallin, PhDa, Malcolm Sue-Chu, PhDb, Leif Bjermer,

Comparison of the efficacy of budesonide and fluticasone propionate aqueous nasal spray for once daily treatment of perennial allergic rhinitis James.

Harold B. Kaiser, MDa, Steven R. Findlay, MD†, John W

Elephantiasis nostras: A case report

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Inhaled fluticasone propionate delivered by means of two different multidose powder inhalers is effective and safe in a large pediatric population with.

Low-dose levalbuterol in children with asthma: Safety and efficacy in comparison with placebo and racemic albuterol Henry Milgrom, MDa, David P. Skoner,

Conjunctivitis medicamentosa

Paul Van Durme, MDa, Jan L. Ceuppens, MD, PhDa,b, Pascal Cadot, PhDb

Side effects of inhaled corticosteroids

Michael Mellon, MD Journal of Allergy and Clinical Immunology

Efficacy and safety of budesonide inhalation suspension (Pulmicort Respules) in young children with inhaled steroid–dependent, persistent asthma Gail.

Marc D. Silverstein, MDa,b, John W. Yunginger, MDc, Charles E

Practice Notes from the AAAAI

Increased sensitivity to bradykinin among African Americans

Paul M. O’Byrne, MB, FRCPI, FRCP(C)a, Soren Pedersen, MD, PhDb

Phillip Lieberman, MD, Michael Tankersley, MD

A review of the current guidelines for allergic rhinitis and asthma

Physician-targeted program on inhaled therapy for childhood asthma

News & Notes Journal of Allergy and Clinical Immunology

James P. Kemp, MDa, David A. Cook, MDb, Gary A

Inflammatory cells, cytokine and chemokine expression in asthma immunocytochemistry and in situ hybridization Qutayba Hamid, MD, PhD, Editor Journal.

Salmeterol and fluticasone propionate combined in a new powder inhalation device for the treatment of asthma: A randomized, double-blind, placebo-controlled.

Inhaled mometasone furoate reduces oral prednisone requirements while improving respiratory function and health-related quality of life in patients with.

Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study) Christian Möller, MD, PhDa, Sten.

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma William.

Subjective and objective assessments in patients with seasonal allergic rhinitis: Effects of therapy with mometasone furoate nasal spray Eli O. Meltzer,

Fluticasone propionate powder administered through Diskhaler versus triamcinolone acetonide aerosol administered through metered-dose inhaler in patients.

Thomas B. Casale, MDa, I. Leonard Bernstein, MDb, William W

A comparison of multiple doses of fluticasone propionate and beclomethasone dipropionate in subjects with persistent asthma Gordon D. Raphael, MDa, Robert.

News & Notes Journal of Allergy and Clinical Immunology

Fluticasone propionate powder: Oral corticosteroid–sparing effect and improved lung function and quality of life in patients with severe chronic asthma

Quantitation of H1-receptor antagonists in skin and serum

A placebo- and active-controlled randomized trial of prophylactic treatment of seasonal allergic rhinitis with mometasone furoate aqueous nasal spray

Low-dose inhaled fluticasone propionate versus oral zafirlukast in the treatment of persistent asthma Eugene R. Bleecker, MDa, Michael J. Welch, MDb,

Inhaled corticosteroids and allergy specialty care reduce emergency hospital use for asthma Michael Schatz, MD, MSa, E.Francis Cook, DScb, Randy Nakahiro,

Omalizumab improves asthma-related quality of life in patients with severe allergic asthma Albert Finn, MDa, Gary Gross, MDb, Julius van Bavel, MDc,

Steroid-sparing effects of fluticasone propionate 100 μg and salmeterol 50 μg administered twice daily in a single product in patients previously controlled.

Thomas A. E. Platts-Mills, MD, PhD, Richard B. Sporik, MD, Lisa M

Preparing patients and health professionals for the transition to chlorofluorocarbon-free inhalers: The British perspective Helen Donohoe, MSc (Econ)

Mite allergen control with acaricide fails

Practice Notes from the AAAI

Mometasone furoate administered once daily is as effective as twice-daily administration for treatment of mild-to-moderate persistent asthma James P.

Abnormalities of cell and mediator levels in bronchoalveolar lavage fluid of patients with mild asthma Sally E. Wenzel, MD Journal of Allergy and Clinical.

Further studies on the chronotherapy of asthma with inhaled steroids: The effect of dosage timing on drug efficacy Diane J. Pincus, MD, Teresa R. Humeston,

Diane J. Pincus, MD, Stanley J. Szefler, MD, Lynn M

Managing asthma exacerbations in the emergency department: Summary of the National Asthma Education and Prevention Program Expert Panel Report 3 guidelines.

Larry C. Borish, MDa, Harold S

Andrea J. Apter, MD, MSca, c, Susan T

Tiotropium is noninferior to salmeterol in maintaining improved lung function in B16- Arg/Arg patients with asthma Eric D. Bateman, MD, Oliver Kornmann,

Airway remodeling-associated mediators in moderate to severe asthma: Effect of steroids on TGF-β, IL-11, IL-17, and type I and type III collagen expression

Asthma symptoms and airway hyperresponsiveness are lower during treatment with nedocromil sodium than during treatment with regular inhaled albuterol

Concomitant montelukast and loratadine as treatment for seasonal allergic rhinitis: A randomized, placebo-controlled clinical trial Eli O. Meltzer, MDa,

News & Notes Journal of Allergy and Clinical Immunology

Comparative efficacy and safety of a once-daily loratadine-pseudoephedrine combination versus its components alone and placebo in the management of seasonal.

Natural history of cow’s milk allergy

Presentation transcript:

The effectiveness of once-daily dosing of inhaled flunisolide in maintaining asthma control Richard L. ZuWallack, MD a,b, James P. Rosen, MDc, Leonard Cohen, MD, PhDb, Gary S. Rachelefsky, MDd, Henry Gong, MDe, Alan B. Goldsobel, MDf,g, Michael A. Kaliner, MDh, Martha V. White, MDh, Edwin A. Bronsky, MDi, Paul Chervinsky, MDj, Gary Z. Lotner, MDk, Jonathan Corren, MDl, Saul Bodenheimer, MDm Journal of Allergy and Clinical Immunology Volume 99, Issue 3, Pages 278-285 (March 1997) DOI: 10.1016/S0091-6749(97)70043-5 Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 1 Mean morning (top graph) and evening (bottom graph) symptoms for the study patients for the baseline period and the 3 study months. Asthma symptoms were rated on a scale of 0 to 3: 0 indicated no symptoms; 1, mild symptoms; 2, moderate symptoms; and 3, severe symptoms. Probability (p) values for end-point data are given in Table II. Journal of Allergy and Clinical Immunology 1997 99, 278-285DOI: (10.1016/S0091-6749(97)70043-5) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 2 Mean daytime (top graph) and nighttime (bottom graph) albuterol requirements. Albuterol use is indicated in inhalations per day for the baseline period and the 3 study months. Probability (p) values for end-point data are given in Table II. Journal of Allergy and Clinical Immunology 1997 99, 278-285DOI: (10.1016/S0091-6749(97)70043-5) Copyright © 1997 Mosby, Inc. Terms and Conditions

Fig. 3 Mean morning (top graph) and evening (bottom graph) PEFR, in liters per minute, for the baseline period and the 3 study months. Probability (p) values for end-point data are given in Table II. Journal of Allergy and Clinical Immunology 1997 99, 278-285DOI: (10.1016/S0091-6749(97)70043-5) Copyright © 1997 Mosby, Inc. Terms and Conditions